AxoGen (AXGN) Stock Forecast & Price Target

Compare

473 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AXGN Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

AxoGen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AXGN Stock 12 Month Forecast

Average Price Target

$37.67

▲(26.49% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for AxoGen in the last 3 months. The average price target is $37.67 with a high forecast of $40.00 and a low forecast of $34.00. The average price target represents a 26.49% change from the last price of $29.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","17":"$17","25":"$25","33":"$33","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,17,25,33,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.53,29.412307692307692,30.294615384615387,31.176923076923078,32.05923076923077,32.941538461538464,33.823846153846155,34.706153846153846,35.58846153846154,36.47076923076923,37.35307692307693,38.23538461538462,39.11769230769231,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.53,29.233076923076926,29.936153846153847,30.63923076923077,31.342307692307692,32.04538461538462,32.74846153846154,33.45153846153846,34.15461538461538,34.85769230769231,35.56076923076923,36.26384615384616,36.96692307692308,{"y":37.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.53,28.950769230769232,29.371538461538464,29.792307692307695,30.213076923076922,30.633846153846154,31.054615384615385,31.475384615384616,31.896153846153847,32.316923076923075,32.737692307692306,33.15846153846154,33.57923076923077,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$37.67

Lowest Price Target$34.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Caitlin Roberts

Canaccord Genuity

$27→$37

Buy

24.24%

Upside

Reiterated

12/05/25

Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (NASDAQ: MPLT), AxoGen (NASDAQ: AXGN) and Ocular Therapeutix (NASDAQ: OCUL)

Yi Chen

H.C. Wainwright

$26→$39

Buy

30.96%

Upside

Reiterated

12/05/25

AxoGen price target raised to $39 from $26 at H.C. WainwrightAxoGen price target raised to $39 from $26 at H.C. Wainwright

Frank Takkinen

Lake Street

$30→$40

Buy

34.32%

Upside

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Inotiv (NASDAQ: NOTV), Eton Pharmaceuticals (NASDAQ: ETON) and AxoGen (NASDAQ: AXGN)We are increasing our PT to $40

Michael Sarcone

Jefferies

$29→$36

Buy

20.89%

Upside

Reiterated

12/04/25

AxoGen price target raised to $36 from $29 at JefferiesAxoGen price target raised to $36 from $29 at Jefferies

Anthony Petrone

Mizuho Securities

$40

Buy

34.32%

Upside

Initiated

12/01/25

AxoGen initiated with an Outperform at MizuhoAxoGen initiated with an Outperform at Mizuho

David Turkaly

Citizens JMP

$26→$34

Buy

14.17%

Upside

Reiterated

10/30/25

AxoGen price target raised to $34 from $26 at Citizens JMPAxoGen price target raised to $34 from $26 at Citizens JMP

Jayson Bedford

Raymond James

$20

Buy

-32.84%

Downside

Reiterated

08/25/25

Raymond James Sticks to Their Buy Rating for AxoGen (AXGN)Raymond James analyst Jayson Bedford reiterated an Outperform rating and $20.00 price target on AxoGen, Inc. (NASDAQ: AXGN).

Mike Kratky

Leerink Partners

$22

Buy

-26.12%

Downside

Reiterated

08/25/25

Optimistic Buy Rating for AxoGen Amid Regulatory Delays and Market Potential

Ross Osborn

Cantor Fitzgerald

$23→$26

Buy

-12.69%

Downside

Reiterated

08/11/25

Cantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN)Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $26.00 price target on AxoGen, Inc. (NASDAQ: AXGN).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Caitlin Roberts

Canaccord Genuity

$27→$37

Buy

24.24%

Upside

Reiterated

12/05/25

Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (NASDAQ: MPLT), AxoGen (NASDAQ: AXGN) and Ocular Therapeutix (NASDAQ: OCUL)

Yi Chen

H.C. Wainwright

$26→$39

Buy

30.96%

Upside

Reiterated

12/05/25

AxoGen price target raised to $39 from $26 at H.C. WainwrightAxoGen price target raised to $39 from $26 at H.C. Wainwright

Frank Takkinen

Lake Street

$30→$40

Buy

34.32%

Upside

Reiterated

12/04/25

Analysts Offer Insights on Healthcare Companies: Inotiv (NASDAQ: NOTV), Eton Pharmaceuticals (NASDAQ: ETON) and AxoGen (NASDAQ: AXGN)We are increasing our PT to $40

Michael Sarcone

Jefferies

$29→$36

Buy

20.89%

Upside

Reiterated

12/04/25

AxoGen price target raised to $36 from $29 at JefferiesAxoGen price target raised to $36 from $29 at Jefferies

Anthony Petrone

Mizuho Securities

$40

Buy

34.32%

Upside

Initiated

12/01/25

AxoGen initiated with an Outperform at MizuhoAxoGen initiated with an Outperform at Mizuho

David Turkaly

Citizens JMP

$26→$34

Buy

14.17%

Upside

Reiterated

10/30/25

AxoGen price target raised to $34 from $26 at Citizens JMPAxoGen price target raised to $34 from $26 at Citizens JMP

Jayson Bedford

Raymond James

$20

Buy

-32.84%

Downside

Reiterated

08/25/25

Raymond James Sticks to Their Buy Rating for AxoGen (AXGN)Raymond James analyst Jayson Bedford reiterated an Outperform rating and $20.00 price target on AxoGen, Inc. (NASDAQ: AXGN).

Mike Kratky

Leerink Partners

$22

Buy

-26.12%

Downside

Reiterated

08/25/25

Optimistic Buy Rating for AxoGen Amid Regulatory Delays and Market Potential

Ross Osborn

Cantor Fitzgerald

$23→$26

Buy

-12.69%

Downside

Reiterated

08/11/25

Cantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN)Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $26.00 price target on AxoGen, Inc. (NASDAQ: AXGN).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AxoGen

1 Month

xxx

Success Rate

8/13 ratings generated profit

Average Return

+12.84%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +12.84% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+21.84%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +21.84% per trade.

1 Year

Mike KratkyLeerink Partners

Success Rate

13/13 ratings generated profit

Average Return

+117.74%

reiterated a buy rating 4 months ago

Copying Mike Kratky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +117.74% per trade.

2 Years

xxx

Success Rate

13/13 ratings generated profit

Average Return

+193.69%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +193.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXGN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AXGN has received 12 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. AXGN average Analyst price target in the past 3 months is 37.67.

Each month's total comprises the sum of three months' worth of ratings.

AXGN Financial Forecast

AXGN Earnings Forecast

Next quarter’s earnings estimate for AXGN is $0.06 with a range of $0.03 to $0.10. The previous quarter’s EPS was $0.12. AXGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AXGN has Performed in-line its overall industry.

AXGN Sales Forecast

Next quarter’s sales forecast for AXGN is $58.02M with a range of $57.50M to $59.80M. The previous quarter’s sales results were $60.08M. AXGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AXGN has Performed in-line its overall industry.

AXGN Stock Forecast FAQ

What is AXGN’s average 12-month price target, according to analysts?

Based on analyst ratings, AxoGen’s 12-month average price target is 37.67.

What is AXGN’s upside potential, based on the analysts’ average price target?

AxoGen has 26.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AXGN a Buy, Sell or Hold?

AxoGen has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is AxoGen’s price target?

The average price target for AxoGen is 37.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $34.00. The average price target represents 26.49% Increase from the current price of $29.78.

What do analysts say about AxoGen?

AxoGen’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of AXGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

AxoGen (AXGN) Stock Forecast & Price Target

AXGN Analyst Ratings

AXGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AxoGen

AXGN Analyst Recommendation Trends

AXGN Financial Forecast

AXGN Earnings Forecast

AXGN Sales Forecast

AXGN Stock Forecast FAQ

Detailed List of Analyst Forecasts